Back to Authors

Tedford, Ryan J.

https://orcid.org/0000-0001-9045-7722

Mayo Clinic

Medical University of South Carolina

Citations 17

A Roadmap for Therapeutic Discovery in Pulmonary Hypertension Associated with Left Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function
Pollesello, Piero , Anker, Markus S. , Backs, Johannes , Bayés‐Genís, Antoni , González, Aránzazu , Maack, Cristoph, Madden, Brendan , Redfield, Margaret M. , Rich, Stuart , Schiattarella, Gabriele G. , Skaara, Hall, Stellos, Konstantinos , Vachiéry, Jean Luc, Meer, Peter van der, Linthout, Sophie Van , Pruszczyk, Piotr , Seferović, Petar , Metra, Marco , Rosano, Giuseppe, Tocchetti, Carlo G. , Schiattarella, Gabriele G. , Stellos, Konstantinos , Metra, Marco , Tocchetti, Carlo Gabriele , Ameri, Pietro , Mercurio, Valentina , Borlaug, Barry A. , Burkhoff, Daniel , Caravita, Sergio , Chan, Stephen Y. , Man, Frances S. de , Giannakoulas, George , Guazzi, Marco , Hassoun, Paul M. , Hemnes, Anna R. , Melenovský, Vojtěch , Müller, Oliver Josef , Papp, Zoltán , Pullamsetti, Soni Savai , Rainer, Peter P. , Tedford, Ryan J. , Thum, Thomas , Vachiéry, Jean‐Luc , Meer, Peter van der , Coats, Andrew J.S. , Rosenkranz, Stephan

European Journal of Heart Failure | April 19, 2024 | Volume: 26 | Issue: 4 | Pages: 707-729

10.1002/ejhf.3236 Get It

Abstract Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
Differences in Donor Heart Acceptance by Race and Gender of Patients on the Transplant Waiting List
Breathett, Khadijah , Mohammed, Selma F. , Mazimba, Sula , Hicks, Albert, Morris, Alanna A. , Colvin, Monica , Daly, Richard C. , Dunlay, Shannon M. , Breathett, Khadijah , Colvin, Monica M , Knapp, Shannon M , Lewsey, Sabra C , Ilonze, Onyedika John , Tedford, Ryan J.

JAMA | March 25, 2024 | Volume: 331 | Issue: 16 | Pages: 1379

10.1001/jama.2024.0065 Get It

ImportanceBarriers to heart transplant must be overcome prior to listing. It is unclear why Black men and women remain less likely to receive a heart transplant after listing than White men and women.ObjectiveTo evaluate whether race or gender of a heart transplant candidate (ie, patient on the transplant waiting list) is associated with the probability of a donor heart being accepted by the transplant center team with each offer.Design, Setting, and ParticipantsThis cohort study used the United Network for Organ Sharing datasets to identify organ acceptance with each offer for US non-Hispanic Black (hereafter, Black) and non-Hispanic White (hereafter, White) adults listed for heart transplant from October 18, 2018, through March 31, 2023.ExposuresBlack or White race and gender (men, women) of a heart transplant candidate.Main Outcomes and MeasuresThe main outcome was heart offer acceptance by the transplant center team. The number of offers to acceptance was assessed using discrete time-to-event analyses, nonparametrically (stratified by race and gender) and parametrically. The hazard probability of offer acceptance for each offer was modeled using generalized linear mixed models adjusted for candidate-, donor-, and offer-level variables.ResultsAmong 159 177 heart offers with 13 760 donors, there were 14 890 candidates listed for heart transplant; 30.9% were Black, 69.1% were White, 73.6% were men, and 26.4% were women. The cumulative incidence of offer acceptance was highest for White women followed by Black women, White men, and Black men (P < .001). Odds of acceptance were less for Black candidates than for White candidates for the first offer (odds ratio [OR], 0.76; 95% CI, 0.69-0.84) through the 16th offer. Odds of acceptance were higher for women than for men for the first offer (OR, 1.53; 95% CI, 1.39-1.68) through the sixth offer and were lower for the 10th through 31st offers.Conclusions and RelevanceThe cumulative incidence of heart offer acceptance by a transplant center team was consistently lower for Black candidates than for White candidates of the same gender and higher for women than for men. These disparities persisted after adjusting for candidate-, donor-, and offer-level variables, possibly suggesting racial and gender bias in the decision-making process. Further investigation of site-level decision-making may reveal strategies for equitable donor heart acceptance.
Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations
Brener, Michael I. , Masoumi, Amirali, Ng, Vivian G., Tello, Khodr , Bastos, Marcelo B. , Cornwell, William K. , Hsu, Steven , Tedford, Ryan J. , Lurz, Philipp , Rommel, Karl-Philipp , Kresoja, Karl-Patrik , Nagueh, Sherif F. , Kanwar, Manreet , Kapur, Navin K. , Hiremath, Gurumurthy , Sarraf, Mohammad, Enden, Antoon J.M. Van Den, Heerdt, Paul M., Kodali, Susheel K., Uriel, Nir , Kanwar, Manreet K , Van Mieghem, Nicolas M , Hahn, Rebecca T , Sayer, Gabriel T , Uriel, Nir , Burkhoff, Daniel , Lurz, Philipp , Tedford, Ryan J , Brener, Michael I. , Masoumi, Amirali, Ng, Vivian G., Tello, Khodr , Bastos, Marcelo B. , Cornwell, William K. , Hsu, Steven , Rommel, Karl-Philipp , Kresoja, Karl-Patrik , Nagueh, Sherif F. , Kapur, Navin K , Hiremath, Gurumurthy , Sarraf, Mohammad, Enden, Antoon J.M. Van Den, Heerdt, Paul M., Kodali, Susheel K.

Circulation: Heart Failure | December 29, 2021 | Volume: 15 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.121.009101 Get It

Right ventricular pressure-volume (PV) analysis characterizes ventricular systolic and diastolic properties independent of loading conditions like volume status and afterload. While long-considered the gold-standard method for quantifying myocardial chamber performance, it was traditionally only performed in highly specialized research settings. With recent advances in catheter technology and more sophisticated approaches to analyze PV data, it is now more commonly used in a variety of clinical and research settings. Herein, we review the basic techniques for PV loop measurement, analysis, and interpretation with the aim of providing readers with a deeper understanding of the strengths and limitations of PV analysis. In the second half of the review, we detail key scenarios in which right ventricular PV analysis has influenced our understanding of clinically relevant topics and where the technique can be applied to resolve additional areas of uncertainty. All told, PV analysis has an important role in advancing our understanding of right ventricular physiology and its contribution to cardiovascular function in health and disease.
Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease
Tang, W.H. Wilson , Wilcox, Jennifer , Jacob, Miriam , Frantz, Robert P. , Hill, Nicholas S. , Singh, Harsimran , Xiao, Lei , Rischard, Franz , Group, the PVDOMICS Study, Tang, W H Wilson , Frantz, Robert P , Rischard, Franz P , Wilcox, Jennifer D , Rosenzweig, Erika B. , Borlaug, Barry A. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Systrom, David M , Tedford, Ryan J. , Vanderpool, Rebecca , Waxman, Aaron B. , Leopold, Jane A. , Group, the PVDOMICS Study

Circulation: Heart Failure | February 24, 2020 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/circheartfailure.119.006363 Get It

Background: Invasive hemodynamic evaluation through right heart catheterization plays an essential role in the diagnosis, categorization, and risk stratification of patients with pulmonary hypertension. Methods: Subjects enrolled in the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) program undergo an extensive invasive hemodynamic evaluation that includes repeated measurements at rest and during several provocative physiological challenges. It is a National Institutes of Health/National Heart, Lung, and Blood Institute initiative to reclassify pulmonary hypertension groups based on clustered phenotypic and phenomic characteristics. At a subset of centers, participants also undergo an invasive cardiopulmonary exercise test to assess changes in hemodynamics and gas exchange during exercise. Conclusions: When coupled with other physiological testing and blood -omic analyses involved in the PVDOMICS study, the comprehensive right heart catheterization protocol described here holds promise to clarify the diagnosis and clustering of pulmonary hypertension patients into cohorts beyond the traditional 5 World Symposium on Pulmonary Hypertension groups. This article will describe the methods applied for invasive hemodynamic characterization in the PVDOMICS program. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02980887.
Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease
Shah, Sanjiv J. , Borlaug, Barry A. , Leary, Peter J. , Patel, Harnish, Kelemen, Benjamin W., Houston, Brian A. , Damico, Rachel L. , Mathai, Stephen C. , Kasper, Edward K. , Tampakakis, Emmanouil, Patel, Harnish H, Miller, Wayne L. , Kolb, Todd M. , Damico, Rachel, Kass, David A. , Borlaug, Barry A , Leary, Peter J , Shah, Sanjiv J , Tampakakis, Emmanouil , Hassoun, Paul M. , Tedford, Ryan J. , Mathai, Stephen C

Circulation: Heart Failure | April 11, 2018 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.117.004436 Get It

Background: Patients with combined post- and precapillary pulmonary hypertension due to left heart disease have a worse prognosis compared with isolated postcapillary. However, it remains unclear whether increased mortality in combined post- and precapillary pulmonary hypertension is simply a result of higher total right ventricular load. Pulmonary effective arterial elastance (Ea) is a measure of total right ventricular afterload, reflecting both resistive and pulsatile components. We aimed to test whether pulmonary Ea discriminates survivors from nonsurvivors in patients with pulmonary hypertension due to left heart disease and if it does so better than other hemodynamic parameters associated with combined post- and precapillary pulmonary hypertension. Methods and Results: We combined 3 large heart failure patient cohorts (n=1036) from academic hospitals, including patients with pulmonary hypertension due to heart failure with preserved ejection fraction (n=232), reduced ejection fraction (n=335), and a mixed population (n=469). In unadjusted and 2 adjusted models, pulmonary Ea more robustly predicted mortality than pulmonary vascular resistance and the transpulmonary gradient. Along with pulmonary arterial compliance, pulmonary Ea remained predictive of survival in patients with normal pulmonary vascular resistance. The diastolic pulmonary gradient did not predict mortality. In addition, in a subset of patients with echocardiographic data, Ea and pulmonary arterial compliance were better discriminators of right ventricular dysfunction than the other parameters. Conclusions: Pulmonary Ea and pulmonary arterial compliance more consistently predicted mortality than pulmonary vascular resistance or transpulmonary gradient across a spectrum of left heart disease with pulmonary hypertension, including patients with heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, and pulmonary hypertension with a normal pulmonary vascular resistance.
Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
Tedford, Ryan J. , Mathai, Stephen C. , Girgis, Reda E. , Thiemann, David R. , Cingolani, Oscar H. , Mudd, James O., Redfield, Margaret M. , Lederer, David J. , Hassoun, Paul M. , Russell, Stuart D. , Borlaug, Barry A. , Kass, David A. , Lederer, David J , Tedford, Ryan J , Mathai, Stephen C

Circulation | December 2, 2011 | Volume: 125 | Issue: 2 | Pages: 289-297

10.1161/circulationaha.111.051540 Get It

Background— Right ventricular failure from increased pulmonary vascular loading is a major cause of morbidity and mortality, yet its modulation by disease remains poorly understood. We tested the hypotheses that, unlike the systemic circulation, pulmonary vascular resistance (R PA ) and compliance (C PA ) are consistently and inversely related regardless of age, pulmonary hypertension, or interstitial fibrosis and that this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ventricular pulsatile load. Methods and Results— Several large clinical databases with right heart/pulmonary catheterization data were analyzed to determine the R PA -C PA relationship with pulmonary hypertension, pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure. Patients with suspected or documented pulmonary hypertension (n=1009) and normal pulmonary capillary wedge pressure displayed a consistent R PA -C PA hyperbolic (inverse) dependence, C PA =0.564/(0.047+R PA ), with a near-constant resistance-compliance product (0.48±0.17 seconds). In the same patients, the systemic resistance-compliance product was highly variable. Severe pulmonary fibrosis (n=89) did not change the R PA -C PA relation. Increasing patient age led to a very small but statistically significant change in the relation. However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger impact, significantly lowering C PA for any R PA and negatively correlating with the resistance-compliance product ( P <0.0001). Conclusions— Pulmonary hypertension and pulmonary fibrosis do not significantly change the hyperbolic dependence between R PA and C PA , and patient age has only minimal effects. This fixed relationship helps explain the difficulty of reducing total right ventricular afterload by therapies that have a modest impact on mean R PA . Higher pulmonary capillary wedge pressure appears to enhance net right ventricular afterload by elevating pulsatile, relative to resistive, load and may contribute to right ventricular dysfunction.